Drug Trial Radar · NCT03752138
TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia
Last checked: Nov 19, 2026Latest source record: May 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Mar 31, 2019
Primary completion
Dec 31, 2020
Study completion Dec 31, 2020
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Nov 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the side effects and best dose of TK216 and decitabine when given together in treating patients with acute myeloid leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as TK216 and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions
- Recurrent Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
Interventions
Group 1: TK216Drug
Starting Dose: 288 mg/m2 given by vein on Days 1-7 of a 21 day cycle.
Group 2: TK216Drug
Starting Dose: 144 mg/m2 given by vein on Days 1-7 and 15-21 of a 23 day cycle.
Part 2: Decitabine 10mg/m2Drug
10mg/m2 by vein on Days 1-10 of a 28 day cycle.
Part 2: Decitabine 20 mg/m2Drug
20 mg/m2 by vein on Days 1-10 of a 28 dayi cycle.
Expansion Phase TK216Drug
Expansion cohort will receive the RP2D of TK216
Expansion Phase DecitabineDrug
Expansion cohort will receive the RP2D of Decitabine
Part 2: TK216Drug
Recommended dose from Part 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse eventsTime frame: Up to 30 days
- Response rateTime frame: Up to 30 days
- Overall survivalTime frame: Up to 1 year
- Disease free survivalTime frame: Up to 1 year
- Duration of disease controlTime frame: Up to 1 year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.